Table 2.
The relationship between SIS group and clinicopathological characteristics in the training set.
| Characteristic | Total (N = 944) | Systemic inflammation score | P-value | |
|---|---|---|---|---|
| Low (0) | High (1,2) | |||
| Age (years) | ||||
| ≤48 | 483 (51.2%) | 327 (34.6%) | 156 (16.6%) | 0.477 |
| >48 | 461 (48.8%) | 322 (34.1%) | 139 (14.7%) | |
| Histological type | ||||
| Invasive ductal carcinoma | 822 (87.1%) | 562 (59.6%) | 260 (27.5%) | 0.513 |
| Others | 122 (12.9%) | 87 (9.2%) | 35 (3.7%) | |
| Tumor grade | ||||
| 1 | 27 (2.9%) | 17 (1.8%) | 10 (1.1%) | 0.151 |
| 2 | 650 (68.9%) | 453 (48.0%) | 197 (20.9%) | |
| 3 | 191 (20.2%) | 121 (12.8%) | 70 (7.4%) | |
| Unknown | 76 (8.0%) | 58 (6.1%) | 18 (1.9%) | |
| T stage | ||||
| 0 | 2 (0.1%) | 0 | 2 (0.1%) | 0.006 |
| 1 | 313 (33.2%) | 203 (21.5%) | 110 (11.7%) | |
| 2 | 552 (58.5%) | 401 (42.5%) | 151 (16.0%) | |
| 3 | 43 (4.6%) | 26 (2.8%) | 17 (1.8%) | |
| 4 | 34 (3.6%) | 19 (2.0%) | 15 (1.6%) | |
| N stage | ||||
| 0 | 482 (51.1%) | 330 (35.0%) | 152 (16.1%) | 0.492 |
| 1 | 260 (27.5%) | 187 (19.8%) | 73 (7.7%) | |
| 2 | 121 (12.8%) | 80 (8.5%) | 41 (4.3%) | |
| 3 | 81 (8.6%) | 52 (5.5%) | 29 (3.1%) | |
| Clinical stage | ||||
| 1 | 209 (22.1%) | 139 (14.7%) | 70 (7.4%) | 0.117 |
| 2 | 513 (54.4%) | 367 (38.9%) | 146 (15.5%) | |
| 3 | 222 (23.5%) | 143 (15.1%) | 79 (8.4%) | |
| Molecular subtype | 0.379 | |||
| Luminal A | 205 (21.7%) | 135 (14.3%) | 70 (7.4%) | |
| Luminal B/HER2- | 354 (37.5%) | 241 (25.5%) | 113 (12.0%) | |
| Luminal B/HER2+ | 119 (12.6%) | 91 (9.6%) | 28 (3.0%) | |
| HER2 Enriched | 125 (13.2%) | 86 (9.1%) | 39 (4.1%) | |
| Triple Negative | 141 (15.0%) | 96 (10.2%) | 45 (4.8%) | |
| ER | ||||
| Negative | 281 (29.8%) | 195 (20.7%) | 86 (9.1%) | 0.781 |
| Positive | 663 (70.2%) | 454 (48.1%) | 209 (22.1%) | |
| PR | ||||
| Negative | 359 (38.0%) | 246 (26.0%) | 113 (12.0%) | 0.906 |
| Positive | 585 (62.0%) | 403 (42.7%) | 182 (19.3%) | |
| HER2 | ||||
| Negative | 659 (69.8%) | 446 (47.2%) | 213 (22.6%) | 0.280 |
| Positive | 285 (30.2%) | 203 (21.5%) | 82 (8.7%) | |
| Ki67 | ||||
| Negative | 313 (33.2%) | 208 (22.1%) | 105 (11.1%) | 0.284 |
| Positive | 631 (66.8%) | 441 (46.7%) | 190 (20.1%) | |
| Adjuvant chemotherapy | ||||
| Yes | 787 (83.4%) | 550 (58.3%) | 237 (25.1%) | 0.092 |
| No | 157 (16.6%) | 99 (10.5%) | 58 (6.1%) | |
| Endocrine therapy | ||||
| Yes | 502 (53.2%) | 395 (38.1%) | 143 (15.1%) | 0.133 |
| No | 440 (46.6%) | 289 (30.6%) | 151 (16.0%) | |
| Unknown | 2 (0.2%) | 1 (0.1%) | 1 (0.1%) | |
| Radiotherapy | ||||
| Yes | 246 (26.1%) | 156 (16.6%) | 90 (9.5%) | 0.036 |
| No | 698 (73.9%) | 493 (53.2%) | 205 (21.7%) | |
| Target therapy | ||||
| Yes | 61 (6.5%) | 45 (4.8%) | 16 (1.7%) | 0.382 |
| No | 883 (93.5%) | 604 (64.0%) | 279 (29.5%) | |
P < 0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.